Search Results
Your search for ,iII matches 9602 pages
Showing 9151 - 9200FOLFOXIRI/Bevacizumab Bests FOLFIRI/Bevacizumab in Metastatic Colorectal Cancer
Patients with untreated metastatic colorectal cancer who received FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) had improved survival compared to patients who received FOLFIRI (5-FU, leucovorin, irinotecan) plus bevacizumab in a phase III...
Shorter-Duration Therapy Including Lower-Dose Cyclophosphamide Preserves Efficacy in Newly Diagnosed Low-Risk Rhabdomyosarcoma
Intergroup Rhabdomyosarcoma Study Group (IRSG) studies have shown improved failure-free survival with VAC (vincristine, dactinomycin, and cyclophosphamide) given with a total cumulative cyclophosphamide dose of 26.4 g/m2 compared with VA (vincristine and dactinomycin) in patients with subset 1...
Ipilimumab/Sargramostim Improves Overall Survival vs Ipilimumab Alone in Patients With Advanced Metastatic Melanoma
A randomized clinical trial of patients with advanced metastatic melanoma treated with ipilimumab (Yervoy), an immune checkpoint inhibitor, in combination with sargramostim (Leukine), an immune stimulant, vs ipilimumab alone, has found a 1-year survival rate of 68.9% vs 52.9% in the ipilimumab-only ...
BRAF Inhibitor Dabrafenib Plus MEK Inhibitor Trametinib Improves Outcomes vs Dabrafenib Alone in Previously Untreated BRAF-Mutant Advanced Melanoma
In a phase III trial reported in The New England Journal of Medicine, Long and colleagues found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) improved response rate and progression-free survival compared with dabrafenib alone in...
BRAF Inhibitor Vemurafenib Plus MEK inhibitor Cobimetinib vs Vemurafenib Alone in Previously Untreated BRAF-Mutant Advanced Melanoma
In a phase III trial reported in The New England Journal of Medicine, Larkin and colleagues found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib improved response rate and progression-free survival compared with vemurafenib alone in...
Gemcitabine-Based Treatment Yields Similar Response Rates, Less Toxicity Than DHAP Before Stem Cell Transplant for Relapsed/Refractory Lymphoma
In the NCIC-CTG LY.12 study, a phase III international noninferiority trial reported in the Journal of Clinical Oncology, Crump and colleagues found that gemcitabine, dexamethasone, and cisplatin (GDP) was associated with a noninferior response rate and similar transplantation rate compared with...
Performance of Lung Cancer Low-Dose CT Screening With Increasing Screening Interval in NELSON Trial
The Dutch and Belgian NELSON trial is assessing the effect of increasing interval low-dose computed tomography (CT) screening for lung cancer on lung cancer mortality. In an analysis of screening test performance among Dutch participants reported in Lancet Oncology, Horeweg and colleagues found...
ALSYMPCA Subgroup Analysis: Radium-223 Survival Benefit Irrespective of Prior Docetaxel in Castration-Resistant Prostate Cancer With Bone Metastases
The phase III ALSYMPCA trial showed that radium-223 (Xofigo) increased overall survival vs placebo patients with castration-resistant prostate cancer and symptomatic bone metastases. In a prespecified subgroup analysis reported in The Lancet Oncology, Hoskin et al found that overall survival...
Higher Levels of Lecithin Retinol Acyltransferase Hypermethylation May Correlate With Earlier Stage of Colorectal Cancer
Compared with normal colorectal mucosae, nearly half of colorectal tumors showed medium-to-high levels of lecithin retinol acyltransferase (LRAT) hypermethylation, according to the results of a study reported by Cheng et al in Medical Oncology. This finding was noted more frequent in earlier tumor...
No Progression-Free Survival Benefit of Dacomitinib vs Erlotinib Overall or in KRAS Wild-Type Disease in Pretreated Advanced NSCLC
In a phase III ARCHER 1009 trial reported in The Lancet Oncology, Ramalingam et al found no progression-free survival benefit of the irreversible pan-HER tyrosine kinase inhibitor dacomitinib vs erlotinib among all patients with pretreated non–small cell lung cancer (NSCLC) or among those...
No Survival Benefit With Pan-HER Tyrosine Kinase Inhibitor Dacomitinib vs Placebo in Pretreated Advanced NSCLC
In the phase III NCIC CTG BR.26 Trial reported in The Lancet Oncology, Ellis et al found that treatment with the irreversible pan-HER tyrosine kinase inhibitor dacomitinib was not associated with an overall survival benefit compared with placebo in patients with pretreated advanced or...
Regional Hepatopancreaticobiliary Surgical Program Improves Care in VA System
In a retrospective cohort study reported in JAMA Surgery, Lau et al found that implementation of a multidisciplinary hepatopancreaticobiliary surgical program in a Veterans Affairs (VA) health-care region resulted in improved care and outcomes. The study involved analysis of practices and outcomes ...
First-Line FOLFIRI Improves Time to Treatment Failure and Is Better Tolerated vs ECX in Advanced Gastric Cancer
In a phase III French Intergroup trial reported in the Journal of Clinical Oncology, Guimbaud et al found that FOLFIRI (fluorouracil [5-FU], leucovorin, and irinotecan) significantly prolonged time to treatment failure compared with ECX (epirubicin, cisplatin, and capecitabine) in first-line...
Blood Biomarker May Detect Lung Cancer
A new study shows that patients with stage I to III non–small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract was released today in an online supplement to the journal CHESTand will be...
ASCO Issues Clinical Expert Statement on Cancer Survivorship Care Planning
Efforts at implementing survivorship care plans have met with limited success in oncology practice, in part due to the time required to complete survivorship care plans, lack of role clarity, and lack of reimbursement for time to complete the documents. In response, ASCO convened a Survivorship...
TAS-102 Receives FDA Fast Track Designation for Refractory Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Taiho Oncology’s TAS-102, a novel agent currently under investigation for the treatment of refractory metastatic colorectal cancer. TAS-102 is an oral combination investigational anticancer drug consisting of...
Neratinib Plus Capecitabine Shows Activity in HER2-Positive Metastatic Breast Cancer
Neratinib is an irreversible pan-tyrosine kinase inhibitor with activity against HER1, HER2, and HER4. In a phase I/II trial reported in the Journal of Clinical Oncology, Saura et al found that the combination of neratinib and capecitabine exhibited high activity in patients with trastuzumab...
FDA Grants Lenvatinib Priority Review Designation for Advanced Thyroid Cancer
The U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for lenvatinib mesylate as a treatment for progressive radioactive iodine–refractory differentiated thyroid cancer and granted the application Priority Review status. Lenvatinib is an oral multiple...
FDA Approves Expanded Use of Tilmanocept for Lymphatic Mapping in Solid Tumors
The U.S. Food and Drug Administration (FDA) has approved the Supplemental New Drug Application for the expanded use of technetium 99m tilmanocept (Lymphoseek Injection) for lymphatic mapping in solid tumors and for adding sentinel lymph node detection for breast cancer and melanoma to the approved...
ASCO Endorses Guideline for Molecular Testing to Select Lung Cancer Patients for EGFR and ALK Inhibitor Treatment
ASCO has endorsed the recently developed joint College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association of Molecular Pathologists (AMP) guideline on molecular testing for selection of patients with lung cancer for EGFR and ALK inhibitor ...
Adding Aprepitant to Granisetron/Dexamethasone Reduces Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan Conditioning in Myeloma
In a phase III trial reported in the Journal of Clinical Oncology, Schmitt et al found that adding aprepitant to granisetron and dexamethasone significantly reduced chemotherapy-induced nausea and vomiting in myeloma patients undergoing high-dose melphalan conditioning and autologous stem cell...
PET/CT Scanning May Provide Accurate Staging of Younger Patients With Breast Cancer
In breast cancer patients under the age of 40, positron-emission tomography/computed tomography (PET/CT) scanning may provide accurate clinical staging for stage IIB and III disease, according to the study findings presented by Riedl et al in The Journal of Nuclear Medicine. The utilization of...
Second-Line Bevacizumab/Chemotherapy Improves Progression-Free Survival in Advanced HER2-Negative Breast Cancer
In the phase III TANIA trial reported in The Lancet Oncology, von Minckwitz et al found that adding bevacizumab (Avastin) to chemotherapy in second-line treatment improved progression-free survival after first-line bevacizumab plus chemotherapy in patients with HER2-negative locally recurrent or...
New Findings in Acute Promyelocytic Leukemia
Three studies reported in the Journal of Clinical Oncology provide information on maintenance treatment with the synthetic retinoid tamibarotene in acute promyelocytic leukemia, potential implications of QT interval prolongation related to arsenic trioxide (Trisenox), and potential health-related...
FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...
FDA Approves Netupitant and Palonosetron Combination Capsule for Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) today approved a combination of netupitant and palonosetron (Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. The new drug, also known as NEPA, is a fixed-combination capsule comprised of two agents: oral palonosetron,...
Improved Survival With Maintenance Capecitabine/Bevacizumab vs Bevacizumab Alone in HER2-Negative Metastatic Breast Cancer
Regulatory approval of bevacizumab (Avastin) plus docetaxel in metastatic breast cancer was withdrawn in Europe in February 2011 and in the United States in November 2011. The phase III IMELDA trial comparing maintenance capecitabine/bevacizumab vs bevacizumab after first-line bevacizumab/docetaxel ...
HPV 16/18 Vaccine Shows Protective Efficacy in Women Aged > 25 Years in 4-Year Interim Follow-up of VIVIANE Study
In the 4-year interim follow-up of the VIVIANE study reported in The Lancet by Skinner et al, the human papillomavirus (HPV) 16/18 AS04-adjuvanted vaccine was found to be protective against 6-month persistent infection or cervical intraepithelial neoplasia grade 1 or higher (CIN1+) associated with...
Increased Risk of Fracture After Radical Cystectomy and Urinary Diversion in Older Patients With Bladder Cancer
In a population-based study reported in the Journal of Clinical Oncology, Gupta et al found that radical cystectomy with urinary diversion for bladder cancer is associated with increased risk of bone fracture at any site in Medicare patients. Radical cystectomy and urinary diversion may cause...
TERT Promoter Mutation Associated With Reduced Survival in Nonacral Cutaneous Melanoma
TERT promoter mutations have been found to occur at high frequency in cutaneous melanoma tumor samples, exhibit a UV-signature, and lead to increased TERT gene expression. In a study reported in the Journal of the National Cancer Institute, Griewank et al found that TERT promoter mutation was...
Sex Steroid Hormones May Play a Role in the Development of Aggressive Prostate Cancer
Men with higher estradiol-to-testosterone ratios had a substantially reduced risk of aggressive prostate cancer, whereas men with higher ratios of 2-hydroxyestrone to 16α-hydroxyestrone had an increased risk of such cancer, according to the study findings presented by Black et al in Cancer...
ESMO 2014: Abiraterone Plus Prednisone Significantly Improves Overall Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
A final analysis of the phase III COU-AA-302 trial showed that abiraterone acetate (Zytiga) plus prednisone significantly prolonged overall survival compared to an active control of placebo plus prednisone in men with chemotherapy-naive metastatic castration-resistant prostate cancer. The study,...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
Next-Generation HPV Vaccine May Prevent 90% of Cervical Cancer Cases Worldwide
A study of a nine-valent human papillomavirus (HPV) vaccine that provides protection against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, has found it to be highly safe and efficacious. If vaccination programs with this new-generation vaccine are effectively implemented, approximately 90% of...
Phase II Study Shows Activity of Hypoxia-Activated Alkylating Prodrug in Combination With Doxorubicin in Advanced Soft-Tissue Sarcoma
In a phase II study reported in the Journal of Clinical Oncology, Chawla et al found that the combination of a hypoxia-activated alkylating prodrug (TH-302) and doxorubicin was active in first-line treatment of advanced soft-tissue sarcoma. TH-302 is a prodrug of the cytotoxic alkylating agent...
ESMO 2014: Nivolumab Shows Signs of Superior Response Rate Compared to Standard Chemotherapy in Advanced Melanoma
The monoclonal antibody nivolumab achieved superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progressed after treatment with ipilimumab (Yervoy), according to preliminary data from a phase III trial presented at the ESMO 2014...
ESMO 2014: Phase III Study Confirms Regorafenib’s Survival Benefit in Metastatic Colorectal Cancer
The phase III CONCUR trial of regorafenib (Stivarga) monotherapy in Asian patients with previously treated metastatic colorectal cancer confirmed the overall survival benefit seen in the previous CORRECT trial and in an exploratory analysis suggested the benefit is substantial in patients not...
ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer
For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...
ESMO 2014: Afatinib Improves Progression-Free Survival in Advanced Head and Neck Cancer
The tyrosine kinase inhibitor afatinib (Gilotrif) was significantly superior to methotrexate as second-line therapy in patients with advanced squamous cell carcinoma of the head and neck who progressed after platinum-based chemotherapy, according to results of the LUX-Head & Neck 1 trial. The...
ESMO 2014: Novel Oral Agent Treats Cancer-Related Cachexia in Non–Small Cell Lung Cancer
For the first time, studies show that a drug is effective in treating cancer-related cachexia. Oral anamorelin hydrochloride increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented at the ESMO...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...
ESMO 2014: CLEOPATRA Study Shows ‘Unprecedented’ Survival With Dual HER2 Blockade in Metastatic Breast Cancer
In the final overall survival analysis of the phase III CLEOPATRA trial, patients with HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the ESMO 2014...
European Phase III Trial Suggests Benefit of Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
In a European phase III trial reported in The Lancet, Slotman et al found benefits of thoracic radiotherapy in patients with extensive-stage small cell lung cancer who had responded to chemotherapy and had received prophylactic cranial radiotherapy. Although thoracic radiotherapy did not...
Continuous Lenalidomide/Dexamethasone Improves Progression-Free Survival in Transplant-Ineligible Patients With Myeloma
In the phase III FIRST trial reported in The New England Journal of Medicine, Benboubker et al found that continuous lenalidomide (Revlimid) plus dexamethasone significantly improved progression-free survival vs melphalan/prednisone/thalidomide (Thalomid) in transplant-ineligible myeloma patients....
Pazopanib Maintenance Improves Progression-Free Survival in Ovarian Cancer, but Benefit Limited to Non–East Asian Patients
In a phase III trial reported in the Journal of Clinical Oncology, du Bois et al found that maintenance therapy with the VEGFR and PDGFR inhibitor pazopanib (Votrient) significantly prolonged progression-free survival vs placebo in women with ovarian cancer without progression after first-line...
Adding Pan-Deacetylase Inhibitor Panobinostat to Bortezomib and Dexamethasone Improves Progression-Free Survival in Relapsed Myeloma
In the phase III PANORAMA1 trial reported in The Lancet Oncology, San-Miguel and colleagues found that adding the pan-deacetylase inhibitor panobinostat to bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed or relapsed and refractory multiple...
Second-Line Ramucirumab Plus Paclitaxel Improves Overall Survival in Patients With Advanced Gastric Cancer
The addition of the monoclonal antibody VEGFR-2 antagonist ramucirumab (Cyramza) to paclitaxel led to a statistically significant improvement in median overall survival in patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma in a phase III trial, reported Wilke et al in ...
Male Pattern Baldness at Age 45 May Be Associated With Aggressive Prostate Cancer
In a prospective cohort study in the population of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Zhou et al found that frontal plus moderate vertex baldness at age 45 is associated with increased risk of aggressive prostate cancer. The findings were reported in the...
Improved Outcomes in Myeloma With High-Dose Melphalan Plus Autologous Transplant and Lenalidomide Maintenance
In a phase III trial reported in The New England Journal of Medicine, Palumbo et al found that consolidation therapy with high-dose melphalan plus autologous stem cell transplantation improved progression-free survival and overall survival compared with melphalan/prednisone/lenalidomide (Revlimid)...
Improved Survival with Adjuvant FOLFOX vs Fluorouracil/Leucovorin After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
In a Korean phase II trial reported in The Lancet Oncology, Hong et al found that adjuvant FOLFOX (oxaliplatin, fluorouracil [5-FU], leucovorin) prolonged progression-free survival and overall survival vs 5-FU/leucovorin in patients with locally advanced rectal cancer who had received neoadjuvant...
